[Cryptococosis: clinical epidemiological laboratorial study and fungi varieties in 96 patients]

Rev Soc Bras Med Trop. 2006 May-Jun;39(3):255-8. doi: 10.1590/s0037-86822006000300005.
[Article in Portuguese]

Abstract

Ninety-six patients with cryptococcosis confirmed by clinical and laboratorial diagnosis were assessed in a prospective study in a University Hospital from March 1998 to November 2003; of these, 81.3% were HIV seropositive patients. Cryptococcus neoformans was isolated from different samples, of which the cerebrospinal fluid 74 (77%) was the most frequent. C. neoformans var neoformans was isolated in 89 cases, where as C. neoformans var gattii was isolated in 7. Cryptococcal meningoencephalitis was detected in 56.3% cases. It was the most frequent unique clinical manifestation and the fungus was detected in the bloodstream in 13.5% of the patients. Among the risk factors, AIDS (81.3%) was the most frequently associated with mycosis. Direct examination carried out on 121 samples revealed the microorganism in 98.3% of them, while the culture was positive for all samples. Most of the patients (59.4%) were treated with amphotericin B or with triazoles, however 72.9% of them ended in death, in particular those patients with positive tests for the HIV (62.5%). Nowadays, cryptococcosis has been frequently diagnosed in our region and represents one of the opportunistic diseases with the highest morbidity and mortality rates in patients with AIDS.

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy
  • AIDS-Related Opportunistic Infections / epidemiology*
  • AIDS-Related Opportunistic Infections / microbiology
  • Adult
  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Antifungal Agents / therapeutic use*
  • Brazil / epidemiology
  • Cryptococcosis / drug therapy
  • Cryptococcosis / epidemiology*
  • Cryptococcosis / microbiology
  • Cryptococcus neoformans / classification*
  • Female
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Prospective Studies
  • Risk Factors
  • Sex Distribution

Substances

  • Antifungal Agents